Latest Ratios: P/E Ratio -0.7x · EV/EBITDA N/A · ROE -84.6%. (2005–2026 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2M | $4M | $3M | $3M | $7M | $21M | $30M | $14M | $16M | $33M | $61M |
| Enterprise Value | $514282 | $2M | $-2351210 | $506970 | $4M | $15M | $28M | $12M | $12M | $24M | $44M |
| P/E Ratio → | -0.65 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.11 | 0.18 | 0.19 | 0.24 | 0.50 | 1.68 | 1.59 | 0.81 | 0.82 | 2.00 | 4.72 |
| P/B Ratio | 0.67 | 1.16 | 0.62 | 0.49 | 0.83 | 2.45 | 5.53 | 2.57 | 1.49 | 2.18 | 2.83 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.10 | -0.16 | 0.04 | 0.28 | 1.21 | 1.51 | 0.65 | 0.65 | 1.43 | 3.39 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 38.0% | 38.0% | 38.2% | 37.3% | 33.7% | 31.6% | 35.2% | 45.3% | 46.8% | 43.9% | 44.2% |
| Operating Margin | -12.6% | -12.6% | -26.0% | -36.9% | -34.4% | -46.6% | -18.5% | -41.2% | -59.3% | -85.2% | -101.2% |
| Net Profit Margin | -16.3% | -16.3% | -24.2% | -38.0% | -38.8% | -40.3% | -21.2% | -18.5% | -62.2% | -86.0% | 72.3% |
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -84.6% | -84.6% | -65.5% | -68.5% | -61.8% | -72.3% | -71.9% | -41.1% | -91.4% | -78.0% | 58.8% |
| ROA | -23.0% | -23.0% | -24.3% | -31.2% | -29.4% | -30.1% | -26.7% | -22.8% | -70.1% | -64.2% | 47.2% |
| ROIC | -419.5% | -419.5% | -188.1% | -81.8% | -89.3% | -136.1% | -78.4% | -110.2% | -129.0% | -208.8% | -271.6% |
| ROCE | -26.3% | -26.3% | -36.0% | -39.9% | -35.8% | -49.2% | -33.3% | -71.4% | -84.0% | -74.5% | -80.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.27 | 0.27 | 0.07 | 0.10 | 0.11 | 0.16 | 0.50 | 0.15 | 0.05 | 0.04 | 0.02 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.50 | -1.15 | -0.41 | -0.37 | -0.69 | -0.29 | -0.51 | -0.31 | -0.62 | -0.80 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | -540.80 | -287.42 | -220.50 | -342.64 | -355.95 | -4311.33 |
Net cash position: cash ($2M) exceeds total debt ($842000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.50 | 2.50 | 3.09 | 3.37 | 3.71 | 2.82 | 3.18 | 2.62 | 3.48 | 4.98 | 6.89 |
| Quick Ratio | 1.75 | 1.75 | 2.38 | 2.64 | 2.94 | 2.37 | 2.56 | 2.16 | 2.53 | 4.11 | 6.21 |
| Cash Ratio | 0.50 | 0.50 | 1.31 | 0.84 | 1.03 | 1.27 | 1.03 | 0.78 | 1.03 | 3.09 | 5.31 |
| Asset Turnover | — | 1.40 | 1.04 | 0.86 | 0.82 | 0.67 | 1.24 | 1.23 | 1.31 | 0.87 | 0.50 |
| Inventory Turnover | 3.32 | 3.32 | 3.03 | 2.94 | 3.08 | 3.24 | 4.77 | 4.47 | 2.96 | 3.26 | 3.22 |
| Days Sales Outstanding | — | 47.23 | 96.13 | 171.80 | 70.73 | 69.57 | 54.98 | 80.89 | 66.98 | 33.68 | 59.99 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $2M | $1M | $909000 | $339400 | $265300 | $199600 | $147700 | $92398 | $50332 | $46932 |
Liquidity and dilution risk
Based on current market data, SNOA trades at a price-to-sales multiple of 0.10, which suggests that investors are heavily discounting the company's future revenue potential due to persistent operating losses and the absence of a clear path to positive earnings per share in the near term.
The P/S ratio of 0.10 indicates that the market is pricing the firm as a distressed asset rather than a growth-oriented specialty manufacturer. This valuation level implies that the market remains skeptical of the company's ability to achieve scale, as the lack of a meaningful P/E or EV/EBITDA multiple reflects the absence of core profitability.
According to reported financial data, the company's cash conversion cycle has fluctuated significantly, reaching 90 days in 2026Q4, which indicates that SNOA struggles to efficiently convert its inventory and receivables into cash compared to more established peers in the specialty pharmaceutical sector.
The high days inventory outstanding (DIO) of 98 days in the most recent quarter suggests that product turnover remains sluggish, potentially tying up critical capital in unsold stock. This inefficiency, combined with variable days sales outstanding (DSO), complicates the company's liquidity management and necessitates frequent external financing.
As reported in historical financial statements, SNOA's return on invested capital has remained consistently negative, with figures reaching -17.2% in 2026Q4, highlighting a structural inability to generate returns that exceed the cost of capital required to sustain its manufacturing and marketing operations.
The negative ROIC trend over the last ten quarters suggests that every dollar of capital deployed into the business is currently eroding shareholder value rather than compounding it. This trend warrants further investigation into whether the company's core HOCl technology can ever achieve the margins necessary to justify its capital intensity.
Investors frequently rely on the P/B ratio of 0.61 to suggest undervaluation, yet this metric obscures the reality that the company's book value is rapidly eroding due to a $201 million accumulated deficit, making it a poor indicator of intrinsic value for this specific business model.
The P/B ratio fails to account for the intangible nature of the company's regulatory assets and the high probability of future equity dilution. A more appropriate focus would be the cash burn rate relative to the remaining cash balance, as the book value provides little protection against the ongoing operational insolvency risks.
Includes 30+ ratios · 22 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SNOA stock.
Sonoma Pharmaceuticals, Inc.'s current P/E ratio is -0.7x. The historical average is 28.9x.
Sonoma Pharmaceuticals, Inc.'s return on equity (ROE) is -84.6%. The historical average is -119.1%.
Based on historical data, Sonoma Pharmaceuticals, Inc. is trading at a P/E of -0.7x. Compare with industry peers and growth rates for a complete picture.
Sonoma Pharmaceuticals, Inc. has 38.0% gross margin and -12.6% operating margin.